BIAF

Business Context and Reporting Period

Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: The Company develops noninvasive diagnostic tests for early-stage lung cancer and other lung diseases using flow cytometry and AI. Its primary commercial product is CyPath® Lung, a sputum-based test for lung cancer detection offered through its subsidiary, Precision Pathology Laboratory Services (PPLS). The Company is also advancing companion diagnostics for asthma and COPD and researching therapeutic approaches for cancer.

Key Financial Metrics

Note: The filing text does not provide explicit gross margin percentages, but revenue decreased while operating expenses decreased slightly, resulting in a wider net loss.

Material Changes vs. Prior Period

• Revenue Decline: Consolidated revenue decreased approximately 34% to $6.2 million. This was a strategic decision to discontinue unprofitable general pathology services to improve cost structure and focus on CyPath® Lung.
• Core Product Growth: Despite the overall revenue drop, CyPath® Lung revenue increased 87% to $963,000, driven by a 99% increase in test volume (over 1,200 tests delivered).
• Increased Losses: Net loss widened to $14.9 million from $9.0 million. This was primarily driven by a $3.8 million non-cash loss from the remeasurement of warrant liabilities and increased clinical development costs ($706k vs $322k) related to a pivotal clinical trial.
• Financing Activity: The Company raised approximately $16.9 million in gross proceeds through multiple equity transactions in 2025, including public offerings, a registered direct offering, and a private placement of Series B Convertible Preferred Stock.

Guidance, Outlook, and Risks

Outlook and Management Commentary

• Going Concern: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months following the issuance of the financial statements. Cash resources are estimated to be sufficient only through June 2026 without additional funding.
• Strategic Focus: The Company is executing a three-phase business plan to expand CyPath® Lung nationally and internationally. Phase 2 involves entering broader strategic markets and launching a longitudinal clinical trial (enrolled first patient in March 2026).
• Recent Developments: The Company presented positive research findings for asthma/COPD companion diagnostics and appointed new members to its Medical and Scientific Advisory Board.

Key Risks and Contingencies

• Liquidity Risk: Continued dependence on capital raises to fund operations; failure to secure funding could force curtailment of operations.
• Regulatory Risk: Uncertainty regarding FDA regulation of Laboratory Developed Tests (LDTs). While a federal court vacated an FDA rule in 2025, future legislative or regulatory changes could impose premarket authorization requirements.
• Operational Risk: Reliance on a single laboratory facility (PPLS) and third-party couriers for sample transport.
• Intellectual Property: Risks related to patent protection, enforcement, and potential infringement claims.

Investor Verification Checklist

• Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" going concern opinion and the June 2026 liquidity horizon.
• Revenue Mix: Confirm the trajectory of CyPath® Lung sales growth versus the continued decline of legacy pathology services to ensure the strategic pivot is effective.
• Clinical Trial Progress: Monitor enrollment and data readouts from the new longitudinal clinical trial (NCT07168993) initiated in March 2026, which is critical for broader physician adoption.
• Warrant Liability: Review the impact of warrant reclassifications and potential future fair value adjustments on the income statement.
• Regulatory Status: Track any new FDA guidance or legislative changes regarding LDTs that could affect the commercialization model of CyPath® Lung.